Cargando…
Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
SIMPLE SUMMARY: We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further inte...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069797/ https://www.ncbi.nlm.nih.gov/pubmed/33924696 http://dx.doi.org/10.3390/cancers13081861 |
_version_ | 1783683321351372800 |
---|---|
author | Nordgård, Oddmund Brendsdal Forthun, Rakel Lapin, Morten Grønberg, Bjørn Henning Kalland, Karl Henning Kopperud, Reidun Kristin Thomsen, Liv Cecilie Vestrheim Tjensvoll, Kjersti Gilje, Bjørnar Gjertsen, Bjørn Tore Hovland, Randi |
author_facet | Nordgård, Oddmund Brendsdal Forthun, Rakel Lapin, Morten Grønberg, Bjørn Henning Kalland, Karl Henning Kopperud, Reidun Kristin Thomsen, Liv Cecilie Vestrheim Tjensvoll, Kjersti Gilje, Bjørnar Gjertsen, Bjørn Tore Hovland, Randi |
author_sort | Nordgård, Oddmund |
collection | PubMed |
description | SIMPLE SUMMARY: We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further integration of liquid biopsy methods in clinical practice are discussed, with a special focus on a Nordic Healthcare system. ABSTRACT: Liquid biopsies have emerged as a potential new diagnostic tool, providing detailed information relevant for characterization and treatment of solid cancers. We here present an overview of current evidence supporting the clinical relevance of liquid biopsy assessments. We also discuss the implementation of liquid biopsies in clinical studies and their current and future clinical role, with a special reference to the Nordic healthcare systems. Our considerations are restricted to the most established liquid biopsy specimens: circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Both ctDNA and CTCs have been used for prognostic stratification, treatment choices, and treatment monitoring in solid cancers. Several recent publications also support the role of ctDNA in early cancer detection. ctDNA seems to provide more robust clinically relevant information in general, whereas CTCs have the potential to answer more basic questions related to cancer biology and metastasis. Epidermal growth factor receptor-directed treatment of non-small-cell lung cancer represents a clinical setting where ctDNA already has entered the clinic. The role of liquid biopsies in treatment decisions, standardization of methods, diagnostic performance and the need for further research, as well as cost and regulatory issues were identified as factors that influence further integration in the clinic. In conclusion, substantial evidence supports the clinical utility of liquid biopsies in cancer diagnostics, but further research is still required for a more general application in clinical practice. |
format | Online Article Text |
id | pubmed-8069797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80697972021-04-26 Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System Nordgård, Oddmund Brendsdal Forthun, Rakel Lapin, Morten Grønberg, Bjørn Henning Kalland, Karl Henning Kopperud, Reidun Kristin Thomsen, Liv Cecilie Vestrheim Tjensvoll, Kjersti Gilje, Bjørnar Gjertsen, Bjørn Tore Hovland, Randi Cancers (Basel) Review SIMPLE SUMMARY: We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further integration of liquid biopsy methods in clinical practice are discussed, with a special focus on a Nordic Healthcare system. ABSTRACT: Liquid biopsies have emerged as a potential new diagnostic tool, providing detailed information relevant for characterization and treatment of solid cancers. We here present an overview of current evidence supporting the clinical relevance of liquid biopsy assessments. We also discuss the implementation of liquid biopsies in clinical studies and their current and future clinical role, with a special reference to the Nordic healthcare systems. Our considerations are restricted to the most established liquid biopsy specimens: circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Both ctDNA and CTCs have been used for prognostic stratification, treatment choices, and treatment monitoring in solid cancers. Several recent publications also support the role of ctDNA in early cancer detection. ctDNA seems to provide more robust clinically relevant information in general, whereas CTCs have the potential to answer more basic questions related to cancer biology and metastasis. Epidermal growth factor receptor-directed treatment of non-small-cell lung cancer represents a clinical setting where ctDNA already has entered the clinic. The role of liquid biopsies in treatment decisions, standardization of methods, diagnostic performance and the need for further research, as well as cost and regulatory issues were identified as factors that influence further integration in the clinic. In conclusion, substantial evidence supports the clinical utility of liquid biopsies in cancer diagnostics, but further research is still required for a more general application in clinical practice. MDPI 2021-04-13 /pmc/articles/PMC8069797/ /pubmed/33924696 http://dx.doi.org/10.3390/cancers13081861 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nordgård, Oddmund Brendsdal Forthun, Rakel Lapin, Morten Grønberg, Bjørn Henning Kalland, Karl Henning Kopperud, Reidun Kristin Thomsen, Liv Cecilie Vestrheim Tjensvoll, Kjersti Gilje, Bjørnar Gjertsen, Bjørn Tore Hovland, Randi Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System |
title | Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System |
title_full | Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System |
title_fullStr | Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System |
title_full_unstemmed | Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System |
title_short | Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System |
title_sort | liquid biopsies in solid cancers: implementation in a nordic healthcare system |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069797/ https://www.ncbi.nlm.nih.gov/pubmed/33924696 http://dx.doi.org/10.3390/cancers13081861 |
work_keys_str_mv | AT nordgardoddmund liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT brendsdalforthunrakel liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT lapinmorten liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT grønbergbjørnhenning liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT kallandkarlhenning liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT kopperudreidunkristin liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT thomsenlivcecilievestrheim liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT tjensvollkjersti liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT giljebjørnar liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT gjertsenbjørntore liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem AT hovlandrandi liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem |